Clinical study on Fuzheng Quxie prescription combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer
- Conditions
- on-small cell lung cancer
- Registration Number
- ITMCTR2000003711
- Lead Sponsor
- Shanghai Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
A total of 136 patients with lung cancer were hospitalized in the Department of Oncology, Shanghai traditional Chinese Medicine Hospital from October 2021 to May 2023.
(1) all cases were confirmed by pathology or cytology as stage III b and IV non-small cell lung cancer (NSCLC).
(2) less than 75 years of age.
(3) the estimated survival time is more than 3 months.
(4) General condition PS <= 2.
(5) have the indication of chemotherapy.
(6) stop using other anticancer drugs for more than one month before being selected for observation; patients who have been ineffective in the third-line treatment of western medicine before.
(7) the patient has good knowledge and compliance.
The lung cancer staging standard adopts the revised international staging of lung cancer published by the International Federation for Lung Cancer Research (International Association for the Study of Lung Cancer, IASLC) in 2007.
(1) Failure to take drugs in accordance with the regulations.
(2) Those who are unable to judge the curative effect, or whose data are incomplete and affect the judgment of the curative effect.
(3) Patients with severe impairment of heart, liver and kidney function.
(4) Pregnant or lactating women.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival period;TCM syndrome;Quality of life score;Evaluation standard of curative effect of solid tumor;Pain score;
- Secondary Outcome Measures
Name Time Method